Drugs / BLS-M07
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02195089 | Mar 2014 → Mar 2016 | cervical intraepithelial neoplasia | BioLeaders Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLS-M07 | “We aimed to explore the safety and efficacy of BLS-M07 which is orally administered agent expressing human papillomavirus (HPV) 16 E7 antigen on the surface of Lactobacillus...” PMID 31576684 ↗ Nov 2019 |
| Route | Oral | “BLS-M07 was administered orally” PMID 31576684 ↗ Nov 2019 |